H.C. Wainwright reinstated coverage of Opus Genetics (IRD) with a Buy rating and $8 price target The firm believes inherited retinal disease development presents an efficient path to concise studies offering insight into gene therapy efficacy. The firm believes the company’s 2025 catalysts can give the its platform the appropriate foundation for continued innovation and development over the near-term.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IRD: